For instance, a potent iNOS inhibitor, GW274150, has been used in phase II clinical trials to treat migraine, and NOS inhibitors are known to provide neuroprotection in PD (13) or under conditions of cerebral ischemia and cerebral artery occlusions (62, 63). Here, NOS2 is linked to migraine disorder.